Borean Pharma AS

Borean aims to leverage the trimeric properties of one human protein, tetranectin, to develop second-generation protein therapeutics to treat autoimmune disease and cancer. Its first candidate is a TNF-alpha antagonist in preclinical testing for autoimmune diseases, but the company also has ongoing early work on several undisclosed oncology targets.

Gustav Wieds Vej 10

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By 

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

Revolution’s Next KRAS Drug Shows Promise In NSCLC

 

Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicines could seal its leadership by combining zoldonrasib with other agents in its portfolio.